News
Boehringer buys NBE for €1.18bn, adding cancer ADC expertise
Boehringer Ingelheim has expanded its oncology focus for the second time this week by buying Swiss biotech NBE-Therapeutics, adding an antibody-drug conjugate (ADC) platform led by a drug f